| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3942 |
| Trial ID | NCT06500273 |
| Disease | Large B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | cema-cel|cemacabtagene ansegedleucel |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma |
| Year | 2024 |
| Country | United States |
| Company sponsor | Allogene Therapeutics |
| Other ID(s) | ALLO-501A-202 |
| Cohort 1 | |||||||||||
|
|||||||||||